header logo image


Page 361«..1020..360361362363..370380..»

USC biological imaging innovator elected to National Academy of Medicine > News > USC Dornsife – USC Dornsife College of Letters, Arts and…

October 28th, 2020 10:54 am

Provost Professor Scott Fraser is recognized for developing technology that provides unprecedented views of live organisms, from embryonic development to old age. [3 min read]

Provost Professor Scott Fraser, a recognized innovator whose inventions have found wide use in both scientific and clinical settings, is an elected member of the National Academy of Medicine. (Photo: No Montes.)

Scott Fraser, Provost Professor of Biological Sciences, Biomedical Engineering, Physiology and Biophysics, Stem Cell Biology and Regenerative Medicine, Pediatrics, Radiology and Ophthalmology, has been elected to the National Academy of Medicine.

Fraser, who holds joint appointments at the USC Dornsife College of Letters, Arts and Sciences and USC Viterbi School of Engineering as well as the Elizabeth Garrett Chair in Convergent Bioscience, is one of just 90 researchers chosen from among the worlds leading scientists to become members of the academy.

Professor Scott E. Fraser is a brilliant biophysicist and innovator, said USC Provost Charles F. Zukoski. He is being recognized for groundbreaking advancements in biology and medicine. His research, which centers on imaging and molecular analyses of intact biological systems, serves as inspiration for future generations of engineers, scientists and medical professionals.

Among the reasons for his election, the academy noted Frasers work integrating biophysics, quantitative biology, and molecular imaging to enable unprecedented views of normal function and disease in live organisms, from embryonic development to old age.

Ive always been fascinated by interdisciplinary teams that can bring new insights into old problems by combining the insights from science, engineering and medicine, Fraser said.

Applying tricks from other fields

Fraser, who earned his bachelors degree in physics and his Ph.D. in biophysics, says he gravitated toward research in biology because there are so many open questions, and so many things that have been thought to be impossible to answer but tricks from other fields make the impossible possible, if the team is willing to tackle it together.

Frasers research delves into early development, organogenesis (the process by which internal organs emerge and develop) and medical diagnostics. His work has spawned several start-up companies and has been used in a number of instruments and FDA-approved diagnostics.

We keep our eyes open to translation of the work in the lab to industrial and clinical utility, he said, adding that USCs Alfred E. Mann Institute for Biomedical Engineering and USC Viterbis National Science Foundation-funded Innovation Corps node have both played key roles and offered important instruction on how to best bring their work to potential customers.

In the last year, our IP (intellectual property) has been licensed by a half-dozen different companies, he said. So, we know the work can lead to new instruments, new diagnostics and new techniques.

Fraser said his team works diligently to ensure collaborators in scientific and clinical fields also benefit from their efforts.

We have built the Translational Imaging Center on the University Park campus and the Translational Biomedical Imaging Center at Childrens Hospital Los Angeles to help support users with interests in fields ranging from regenerative medicine to cancer and diabetes. This is already empowering them to make new insights into their research challenges.

What we hope to do is to make it possible for researchers and clinicians to have aha moments, when they can see things for the first time.

A career highlighted by innovation

After earning his Ph.D. in 1979, Fraser joined the faculty at the University of California, Irvine, where he rose through the ranks to become chair of the Department of Physiology and Biophysics. In 1990, he moved to Caltech to serve as the Anna L. Rosen Professor of Biology and the director of the Biological Imaging Center. There, he served as the founding director of both the Caltech Brain Imaging Center and the Rosen Center for Biological Engineering and helped found the Kavli Nanoscience Institute.

In Fall 2012, Fraser moved to USC as Provost Professor at USC Dornsife and USC Viterbi, with formal links to Childrens Hospital Los Angeles and Keck School of Medicine of USC. He serves as the director of science initiatives for USC as well as co-director of the Bridge Institute at the USC Michelson Center for Convergent Bioscience.

A prolific author and inventor, Fraser has more than 240 peer-reviewed articles and more than 75 issued patents to his credit. He is the recipient of numerous honors and has been elected to the National Academy of Inventors, the American Institute for Medical and Biological Engineering, the American Association for the Advancement of Science, the American Academy of Arts and Sciences and the European Academy of Science.

About the National Academy of Medicine

The National Academy of Medicine, established in 1970 as the Institute of Medicine, is an independent organization of professionals from diverse fields including health and medicine, and the natural, social and behavioral sciences. Election to the academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

See the original post:
USC biological imaging innovator elected to National Academy of Medicine > News > USC Dornsife - USC Dornsife College of Letters, Arts and...

Read More...

Orthopedic Regenerative Medicine Market Study Based on Growth, Opportunities, Constraints and Development Factors for Next 5 Years – PRnews Leader

October 28th, 2020 10:54 am

The report also provides an in-depth analysis of the competitive landscape and behavior of market participants. In this way, market participants can familiarize themselves with the current and future competitive scenario of the global market for Orthopedic Regenerative Medicine and take strategic initiatives to gain a competitive advantage. The market analysts have carried out extensive studies using research methods such as PESTLE and Porters Five Forces analysis. Overall, this report can prove to be a useful tool for market participants to gain deep insight into the global market for Orthopedic Regenerative Medicine and to understand the main perspectives and ways to increase their profit margins.

Free Sample Report + All Related Graphs & Charts @: https://www.coherentmarketinsights.com/insight/request-sample/3566

The MAJOR COMPANIES covered in Orthopedic Regenerative Medicine are:

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Orthopedic Regenerative Medicine manufacturing sites, capacity, production, ex-factory price, and revenue and market share in global market.

Orthopedic Regenerative Medicine Market: Segment Analysis:

The report section contains segmentations such as application, product type and end user. These segments help determine which parts of the market will improve over others. This section analysis provides information on the most important aspects of developing certain categories better than others. It helps readers understand strategies to make solid investments. The market for Orthopedic Regenerative Medicine is segmented according to product type, applications and end users.

The end users/applications and product categories analysis:

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Orthopedic Regenerative Medicine for each application, including-

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Get Up to 10-25% Discount on This Premium [emailprotected]: https://www.coherentmarketinsights.com/insight/request-discount/3566

Table of Contents

Part I Orthopedic Regenerative Medicine Industry Overview

Chapter One Orthopedic Regenerative Medicine Industry Overview

1.1 Orthopedic Regenerative Medicine Definition

1.2 Orthopedic Regenerative Medicine Classification Analysis

1.2.1 Orthopedic Regenerative Medicine Main Classification Analysis

1.2.2 Orthopedic Regenerative Medicine Main Classification Share Analysis

1.3 Orthopedic Regenerative Medicine Application Analysis

1.3.1 Orthopedic Regenerative Medicine Main Application Analysis

1.3.2 Orthopedic Regenerative Medicine Main Application Share Analysis

1.4 Orthopedic Regenerative Medicine Industry Chain Structure Analysis

1.5 Orthopedic Regenerative Medicine Industry Development Overview

1.5.1 Orthopedic Regenerative Medicine Product History Development Overview

1.5.1 Orthopedic Regenerative Medicine Product Market Development Overview

1.6 Orthopedic Regenerative Medicine Global Market Comparison Analysis

1.6.1 Orthopedic Regenerative Medicine Global Import Market Analysis

1.6.2 Orthopedic Regenerative Medicine Global Export Market Analysis

1.6.3 Orthopedic Regenerative Medicine Global Main Region Market Analysis

1.6.4 Orthopedic Regenerative Medicine Global Market Comparison Analysis

1.6.5 Orthopedic Regenerative Medicine Global Market Development Trend Analysis

Chapter Two Orthopedic Regenerative Medicine Up and Down Stream Industry Analysis

2.1 Upstream Raw Materials Analysis

2.1.1 Proportion of Manufacturing Cost

2.1.2 Manufacturing Cost Structure of Orthopedic Regenerative Medicine Analysis

2.2 Down Stream Market Analysis

2.2.1 Down Stream Market Analysis

2.2.2 Down Stream Demand Analysis

2.2.3 Down Stream Market Trend Analysis

Part II Asia Orthopedic Regenerative Medicine Industry (The Report Company Including the Below Listed But Not All)

Chapter Three Asia Orthopedic Regenerative Medicine Market Analysis

3.1 Asia Orthopedic Regenerative Medicine Product Development History

3.2 Asia Orthopedic Regenerative Medicine Competitive Landscape Analysis

3.3 Asia Orthopedic Regenerative Medicine Market Development Trend

Chapter Four 2016-2020 Asia Orthopedic Regenerative Medicine Productions Supply Sales Demand Market Status and Forecast

4.1 2016-2020 Orthopedic Regenerative Medicine Production Overview

4.2 2016-2020 Orthopedic Regenerative Medicine Production Market Share Analysis

4.3 2016-2020 Orthopedic Regenerative Medicine Demand Overview

4.4 2016-2020 Orthopedic Regenerative Medicine Supply Demand and Shortage

4.5 2016-2020 Orthopedic Regenerative Medicine Import Export Consumption

4.6 2016-2020 Orthopedic Regenerative Medicine Cost Price Production Value Gross Margin

Chapter Five Asia Orthopedic Regenerative Medicine Key Manufacturers Analysis

5.1 Company A

5.1.1 Company Profile

5.1.2 Product Picture and Specification

5.1.3 Product Application Analysis

5.1.4 Capacity Production Price Cost Production Value

5.1.5 Contact Information

5.2 Company B

5.2.1 Company Profile

5.2.2 Product Picture and Specification

5.2.3 Product Application Analysis

5.2.4 Capacity Production Price Cost Production Value

5.2.5 Contact Information

5.3 Company C

5.3.1 Company Profile

Continued

Download Free PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/3566

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email:[emailprotected]Web:https://www.coherentmarketinsights.com/

Read more:
Orthopedic Regenerative Medicine Market Study Based on Growth, Opportunities, Constraints and Development Factors for Next 5 Years - PRnews Leader

Read More...

Regenerative Medicine Market Size, Growth, Analysis Of Key- players Types And Application, Outlook, Covid-19 Impact by 2026 | Futuristic Reports – The…

October 28th, 2020 10:54 am

Global Regenerative Medicine market report offers a precise outline of the market that includes many aspects of market product definition, market segmentation, analysis, key developments, and existing vendors state of the business. These Regenerative Medicine industry documents include key players and geographical markets that have adopted vital methodologies for business developments and growth. The consumer trust in precise and proper Regenerative Medicine information structures that is employed for analysis of the business Report 2020 has the aim to deliver a complete analysis of the Regenerative Medicine market. The report could assist you in coming up with worthy growth methods and additionally aware and indurate challenges.

Perpetually increasing in the market, often rise in customers demands are the notable factors of growing and developing the business. Taking thought of each segments Regenerative Medicine market report is deliberate by creating each analysis of the market conditions worldwide. Examine the restraining Regenerative Medicine segments affecting the business in the coming future has been into consideration.

Get a Sample Copy of the Report at https://www.futuristicreports.com/request-sample/84632

Impact of COVID-19 on Regenerative Medicine Market

The report also contains the effect of the ongoing worldwide pandemic, i.e., COVID-19, on the Regenerative Medicine Market and what the future holds for it. It offers an analysis of the impacts of the epidemic on the international market. The epidemic has immediately interrupted the requirement and supply series. The report also assesses the economic effect on firms and monetary markets. Futuristic Reports has accumulated advice from several delegates of this business and has engaged from the secondary and primary research to extend the customers with strategies and data to combat industry struggles throughout and after the COVID-19 pandemic.

Global Regenerative Medicine Market: Competitive Landscape

(DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologies, Bellicum Pharmaceuticals)

Segment by Type, the Regenerative Medicine market is segmented into

Cell Therapy Tissue Engineering Biomaterial Other

Segment by Application, the Regenerative Medicine market is segmented into

Dermatology Cardiovascular CNS Orthopedic Others

To Understand How Covid-19 Impact Is Covered in This Report With additional Discount: https://www.futuristicreports.com/check-discount/84632

This report also splits the market by region:

United StatesCanadaMexicoBrazilAPACChinaJapanKorea

Key Questions Answered in The Report:

Market Report includes major TOC points1 Study Coverage1.1 Regenerative Medicine Product Introduction1.2 Market Segments1.3 Key Regenerative Medicine Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Regenerative Medicine Market Size Growth Rate by Type1.4.2 Measuring Smart Plug1.4.3 Regular Smart Plug1.4.4 Remote Control Smart Plug1.4.5 Other1.5 Market by Application1.5.1 Global Regenerative Medicine Market Size Growth Rate by Application1.5.2 Home1.5.3 Commercial1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Regenerative Medicine Market Size, Estimates and Forecasts2.1.1 Global Regenerative Medicine Revenue 2016-20262.1.2 Global Regenerative Medicine Sales 2016-20262.2 Global Regenerative Medicine, Market Size by Producing Regions: 2016 VS 2020 VS 20262.3 Regenerative Medicine Historical Market Size by Region (2016-2020)2.3.1 Global Regenerative Medicine Retrospective Market Scenario in Sales by Region: 2016-20202.3.2 Global Regenerative Medicine Retrospective Market Scenario in Revenue by Region: 2016-20202.4 Regenerative Medicine Market Estimates and Projections by Region (2021-2026)2.4.1 Global Regenerative Medicine Sales Forecast by Region (2021-2026)2.4.2 Global Regenerative Medicine Revenue Forecast by Region (2021-2026)

3 Global Regenerative Medicine Competitor Landscape by Players3.1 Global Top Regenerative Medicine Sales by Manufacturers3.1.1 Global Regenerative Medicine Sales by Manufacturers (2016-2020)3.1.2 Global Regenerative Medicine Sales Market Share by Manufacturers (2016-2020)3.2 Global Regenerative Medicine Manufacturers by Revenue3.2.1 Global Regenerative Medicine Revenue by Manufacturers (2016-2020)3.2.2 Global Regenerative Medicine Revenue Share by Manufacturers (2016-2020)3.2.3 Global Regenerative Medicine Market Concentration Ratio (CR5 and HHI) (2016-2020)3.2.4 Global Top 10 and Top 5 Companies by Regenerative Medicine Revenue in 20193.2.5 Global Regenerative Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Global Regenerative Medicine Price by Manufacturers3.4 Global Regenerative Medicine Manufacturing Base Distribution, Product Types3.4.1 Regenerative Medicine Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Regenerative Medicine Product Type3.4.3 Date of International Manufacturers Enter into Regenerative Medicine Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2016-2026)4.1 Global Regenerative Medicine Market Size by Type (2016-2020)4.1.1 Global Regenerative Medicine Sales by Type (2016-2020)4.1.2 Global Regenerative Medicine Revenue by Type (2016-2020)4.1.3 Regenerative Medicine Average Selling Price (ASP) by Type (2016-2026)4.2 Global Regenerative Medicine Market Size Forecast by Type (2021-2026)4.2.1 Global Regenerative Medicine Sales Forecast by Type (2021-2026)4.2.2 Global Regenerative Medicine Revenue Forecast by Type (2021-2026)4.2.3 Regenerative Medicine Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Regenerative Medicine Market Share by Price Tier (2016-2020): Low-End, Mid-Range, and High-End

5 Market Size by Application (2016-2026)5.1 Global Regenerative Medicine Market Size by Application (2016-2020)5.1.1 Global Regenerative Medicine Sales by Application (2016-2020)5.1.2 Global Regenerative Medicine Revenue by Application (2016-2020)5.1.3 Regenerative Medicine Price by Application (2016-2020)5.2 Regenerative Medicine Market Size Forecast by Application (2021-2026)5.2.1 Global Regenerative Medicine Sales Forecast by Application (2021-2026)5.2.2 Global Regenerative Medicine Revenue Forecast by Application (2021-2026)5.2.3 Global Regenerative Medicine Price Forecast by Application (2021-2026)

..Continued

Inquire or Share Your Questions If Any before the Purchasing This Report https://www.futuristicreports.com/send-an-enquiry/84632

Our Other Reports:

Global Semiconductor Photoresist Stripping Market Research Report

Global Cerebral Oximeters Market Research Report

Polyethylene Market in World Outlook, Dynamics and Forecast, Covid-19 Impact by 2026 | Futuristic Reports

Global Facial Erythema Therapies Market 2020 Competitive Landscape, Trends and Opportunities

Futuristic Reports

Name: Mark RiveraTel: +1-408-520-9037Email: [emailprotected]

Go here to read the rest:
Regenerative Medicine Market Size, Growth, Analysis Of Key- players Types And Application, Outlook, Covid-19 Impact by 2026 | Futuristic Reports - The...

Read More...

MediPharm Labs Sets Date to Release Third Quarter 2020 Financial Results

October 28th, 2020 10:53 am

TORONTO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release third quarter financial results for the three and nine month period ended September 30, 2020 before markets open on Monday, November 16, 2020.

Link:
MediPharm Labs Sets Date to Release Third Quarter 2020 Financial Results

Read More...

G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020

October 28th, 2020 10:52 am

RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2020 on Wednesday, November 4, 2020 at 4:30 p.m. ET.

See the original post:
G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020

Read More...

Verona Pharma plc : Update on AIM Delisting

October 28th, 2020 10:52 am

LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intended Delisting and Cancellation of its Ordinary Shares from Trading on AIM, as announced on September 21, 2020.

Read the rest here:
Verona Pharma plc : Update on AIM Delisting

Read More...

Kraig Biocraft Laboratories Delivers Recombinant Spider Silk Silkworm Eggs to Production Facility in Vietnam

October 28th, 2020 10:52 am

ANN ARBOR, Mich., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announces that it has delivered its latest batch of spider silk silkworm eggs to its production facility in Vietnam.

Read more from the original source:
Kraig Biocraft Laboratories Delivers Recombinant Spider Silk Silkworm Eggs to Production Facility in Vietnam

Read More...

Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update

October 28th, 2020 10:52 am

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter of 2020 and provide a corporate update at 4:30 p.m. ET on November 4, 2020.

Follow this link:
Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update

Read More...

OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators

October 28th, 2020 10:52 am

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Oct. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today the award of a German Federal Government grant to its subsidiary, Curetis GmbH, and collaborators Carpegen GmbH (Muenster, Germany) and the Clinic for Small Animal Internal Medicine of the LMU Ludwig-Maximilians- University (Munich, Germany).

See the original post:
OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators

Read More...

Iovance Biotherapeutics to Present at Upcoming Conferences in November

October 28th, 2020 10:52 am

SAN CARLOS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November:

Read this article:
Iovance Biotherapeutics to Present at Upcoming Conferences in November

Read More...

BetterLife Provides Important Update on its Australian Clinical Study Design

October 28th, 2020 10:52 am

Vancouver, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company preparing human clinical trials of AP-003, its interferon alpha 2b inhalation therapy for the treatment of COVID-19, today provided the following update regarding how it expects to overcome potential challenges of recruiting patients for human trials.

Read the rest here:
BetterLife Provides Important Update on its Australian Clinical Study Design

Read More...

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results

October 28th, 2020 10:52 am

-Reported positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies-

Go here to read the rest:
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results

Read More...

VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th

October 28th, 2020 10:52 am

BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Continued here:
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th

Read More...

Kane Biotech builds upon successful results with launch of a US Consumer Test

October 28th, 2020 10:52 am

WINNIPEG, Manitoba, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech,” or “the Company”) is pleased to announce that the launch of a larger consumer product test to further prove the efficacy of the Company’s shampoo on dermatitis and dandruff began on October 14, 2020.

Read this article:
Kane Biotech builds upon successful results with launch of a US Consumer Test

Read More...

Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America

October 28th, 2020 10:52 am

Read this article:
Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America

Read More...

Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020

October 28th, 2020 10:52 am

WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the presentation of preclinical data highlighting the potential of its modular biologics pipeline for the treatment of autoimmune diseases at the Federation of Clinical Immunology Societies (FOCIS) 2020 virtual annual meeting.

Continue reading here:
Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020

Read More...

Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes

October 28th, 2020 10:52 am

PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions, today announced it has initiated two pilot clinical studies to demonstrate effectiveness of an AAV expressing a GLP-1 analog (SB-009) in treating diabetic felines.

See the article here:
Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes

Read More...

Yield10 Bioscience Announces Start of Field Tests of Winter Camelina Varieties

October 28th, 2020 10:52 am

WOBURN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has begun field testing to evaluate the emergence and agronomics of winter Camelina sativa varieties. The testing of these winter varieties in the 2020/2021 winter season is part of Yield10’s continued development of Camelina sativa in the medium term for use at commercial scale as a cash cover crop for North America.

Continue reading here:
Yield10 Bioscience Announces Start of Field Tests of Winter Camelina Varieties

Read More...

One World’s Dr. Kenneth Perego Joins Montel Williams for Blunt Discussion

October 28th, 2020 10:52 am

LAS VEGAS, NV, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Pharma Inc. (OTC: OWPC), “OWP,” a U.S. based, fully licensed, pure-play hemp and cannabis ingredient producer in Colombia, is pleased to announce that its Executive Chairman, Dr. Kenneth Perego, recently joined television personality and cannabis advocate Montel Williams on his popular podcast “Let’s Be Blunt.”

Continued here:
One World’s Dr. Kenneth Perego Joins Montel Williams for Blunt Discussion

Read More...

AXIM® Biotechnologies Issues Update Letter to Shareholders

October 28th, 2020 10:52 am

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.

Follow this link:
AXIM® Biotechnologies Issues Update Letter to Shareholders

Read More...

Page 361«..1020..360361362363..370380..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick